Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Our first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in nearly 40 countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation. Click here for prescribing information.
As we serve a growing number of patients with PNH and aHUS in our core territories, we also continue to expand our operations into additional countries. And, we are simultaneously developing the most robust pipeline in our history.
Alexion is investigating eculizumab as a treatment for patients with additional life-threatening rare disorders in which the inhibition of terminal complement has potentially transformative benefits for patients. These include disorders in the areas of neurology and transplant.
And, we are investigating other highly innovative therapeutic candidates as treatments for patients with additional severe and rare conditions. These include asfotase alfa for patients with hypophosphatasia; ALXN1007, a novel anti-inflammatory antibody being studied in Gastrointestinal Graft-versus-Host Disease (GI-GVHD) and Antiphospholipid Syndrome (APS); and ALXN1101, a cPMP replacement therapy for patients with molybdenum cofactor deficiency Type A.
Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.
Our global headquarters and research operations are in Cheshire, Conn., and will move to New Haven, Conn. in 2015. Alexion's approximately 2,400 employees serve patients in 50 countries.
Download the Alexion Corporate Brochure